Paul Shapero, MD
Allergy & Immunology · Bangor, MENPI 1164427258
Payments from drug & device makers
Across 776 payments — averaging $1524.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$264K
- LEO Pharma AS$215K
- Novartis$190K
- Sanofi US Services Inc.$156K
- Merck$151K
- GSK$84K
- plus $124K from 20 others
Across 178 payments — averaging $2330.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$172K
- Genentech, Inc.$122K
- Teva Pharmaceuticals USA, Inc.$62K
- Alk-abello, Inc$20K
- Regeneron$19K
- Galderma Research & Development, LLC$11K
- plus $7K from 3 others
What the payments were for
- Consulting fees$1,44011%
- Travel & lodging$1,99316%
- Food & beverage$9,02871%
- Education$3233%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 138 | $263,905 |
| LEO Pharma AS | 43 | $215,155 |
| Novartis | 51 | $189,878 |
| Sanofi US Services Inc. | 45 | $155,557 |
| Merck | 62 | $150,626 |
| GSK | 124 | $84,069 |
| Regeneron | 89 | $56,068 |
| Genentech, Inc. | 6 | $21,583 |
| Shionogi Inc | 11 | $21,057 |
| Galderma Laboratories, L.p. | 7 | $8,267 |
| Chiesi USA, Inc. | 4 | $6,268 |
| Alk-abello, Inc | 11 | $2,057 |
| Genentech USA, Inc. | 7 | $1,931 |
| Regeneron Healthcare Solutions, Inc. | 89 | $1,788 |
| LEO Pharma Inc. | 14 | $1,684 |
| Pfizer | 7 | $1,443 |
| Sanofi | 41 | $771 |
| Amgen(2 entities) | 11 | $222 |
| Boehringer Ingelheim | 6 | $145 |
| Incyte Corporation | 2 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $82 |
| AbbVie | 2 | $48 |
| Pharming Healthcare, Inc. | 2 | $36 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 27 | $108,635 |
| Dupixent SyringeDupilumab | 24 | $90,978 |
| XolairOmalizumab | 31 | $76,819 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $34,979 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,492 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $5,859 |
| Methylprednisolone | 49 | $1,794 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $1,700 |
| Prednisone | 372 | $1,120 |
| Montelukast Sodium | 17 | $326 |
| Azithromycin | 37 | $174 |
| Levocetirizine Dihydrochloride | 14 | $134 |
| Amoxicillin | 33 | $128 |
| Omeprazole | 15 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $21,583 | $76,81931 claims |
| GSKTrelegy Ellipta | $84,069 | $34,97949 claims |
| AstraZenecaBreztri Aerosphere | $263,905 | $7,49211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Maineon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Bangor
- Rung-Chi LiBangor$1.2M
- Jonathan MusmandPortland$239K
- Ivan CardonaPortland$9K
- Calvin FuhrmannKennebunk$7K
- Chelsea MichaudPortland$7K
- Andrew ParkerPortland$6K
- Scott DyerAugusta$3K
- Russell BehmerPortland$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.